Korean drug maker Celltrion announced that it has completed enrollment in its phase 3 clinical trial of CT-P17.
Korean drug maker Celltrion announced that it has completed enrollment in its phase 3 clinical trial of CT-P17, a proposed biosimilar adalimumab, in patients with rheumatoid arthritis (RA).
The company said that it completed enrollment for the study ahead of schedule, which will allow it to complete the trial early, with the aim of an expedited product launch.
The drug maker also noted that it has developed its biosimilar to reflect high-concentration formulations of adalimumab, distinguishing the proposed product from other biosimilar adalimumab options on the market. It is also developing the product to be free of citrates, which are used in some biosimilar adalimumab formulations and which can cause discomfort to the patient during injection.
Separately, Celltrion announced that it has been in discussions with the FDA about its proposed subcutaneous formulation of CT-P13 (Inflectra, Remsima), a biosimilar infliximab product. According to a company statement, phase 1 and phase 2 trials for the subcutaneous formulation of the product will be exempted from the product’s clinical program, and only phase 3 trials will be conducted. The company says that this streamlined plan will reduce development costs and potentially facilitate early US launch of the product.
Celltrion says that it will conduct its phase 3 program in the United States in patients with inflammatory bowel disease, which it called the major indication for the US infliximab market.
In addition to making an appealing choice for patients who are satisfied with treatment with intravenous infliximab but who prefer a subcutaneous route of administration, the new formulation of CT-P13, said Celltrion, could compete with brand-name Humira, another subcutaneously administered anti—tumor necrosis factor therapy.
Currently, the subcutaneous formulation of CT-P13 is under review by the European Medicines Agency (EMA). Celltrion expects the EMA’s Committee for Medicinal Products for Human Use to deliver an opinion on the proposed formulation in the second half of 2019.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim
November 25th 2023A phase 1 analysis confirms that romiplostim biosimilar candidate GP40141 has comparable pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers compared with the reference product.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).